化疗
对于2型神经纤维瘤病患者(即,家族型听神经瘤,患者有双侧病变,有多种其他肿瘤,往往有多种治疗方法),化疗药物(例如,贝伐单抗,厄洛替尼)正在进行试验。然而,就像听神经瘤患者的情况一样,这些药物不能长期使用,它们有中度的不良反应。到目前为止,大多数药物似乎只有几年的短暂效果,且没有用于散发性或单侧听神经瘤患者(例如,非神经纤维瘤病患者)。[28]Plotkin SR, Halpin C, Blakeley JO, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009;93:61-77.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036446/http://www.ncbi.nlm.nih.gov/pubmed/19430883?tool=bestpractice.com[29]Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31:1135-1143.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030413/http://www.ncbi.nlm.nih.gov/pubmed/20736812?tool=bestpractice.com[30]Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33:1046-1052.http://www.ncbi.nlm.nih.gov/pubmed/22805104?tool=bestpractice.com[31]Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358-367.http://www.nejm.org/doi/full/10.1056/NEJMoa0902579#t=articlehttp://www.ncbi.nlm.nih.gov/pubmed/19587327?tool=bestpractice.com